Clinical trialNCT06238648RecruitingPhase 2Interventional

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

SponsorAcademic and Community Cancer Research UnitedEnrollment120Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedPrimary Mediastinal Large B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial compares epcoritamab to standard practice (observation) for the treatment of patients with B-cell lymphomas who are not in complete remission after treatment with CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy. Epcoritamab is a bispecific antibody. It works by simultaneously attaching to a molecule called CD20 on cancerous B-cells and a molecule called CD3 on effector T-cells, which are a type of immune cell. When epcoritamab binds to CD20 and CD3, it brings the two cells together and activates the T-cells to kill the cancerous B-cells. Epcoritamab may increase a patient's chances of achieving complete remission after CD19-directed CAR-T therapy, compared to standard observation.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Grzegorz S Nowakowski
Academic and Community Cancer Research United
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Mayo Clinic in Rochester
Rochester, Minnesota, United States
Grzegorz S. Nowakowski
Not, yet, recruiting
Siteman Cancer Center at Washington University
St Louis, Missouri, United States
Dilan A. Patel
Not, yet, recruiting
Hackensack University Medical Center
Hackensack, New Jersey, United States
Lori Leslie
Not, yet, recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Miguel-Angel Perales
Not, yet, recruiting
Unc Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
Natalie S. Grover
Not, yet, recruiting
Huntsman Cancer Institute/university of Utah
Salt Lake City, Utah, United States
Allison Bock
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Epcoritamab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Jan 2024
Primary completion: 31 Dec 2029
Completion: 31 Dec 2030
Last update posted: 26 Sept 2024
Registered enrollment: 120
Registry id: NCT06238648

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.